LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on SYRE stock, giving a Buy rating on August 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight Spyre Therapeutics’ promising approach in the treatment of inflammatory bowel disease (IBD). Spyre is developing innovative combination therapies that target well-validated pathways in IBD, such as α4β7, TL1A, and IL-23p19, which are believed to offer superior efficacy compared to existing monotherapies. These combinations are designed to optimize dose and target suppression, potentially leading to better patient outcomes.
Moreover, Spyre’s therapies are expected to have a favorable safety profile, as they are TNF-free and JAK-free, reducing the risk of black box warnings and excessive safety monitoring. The dosing frequency of Spyre’s treatments, anticipated to be every 12 weeks or more, adds to their appeal by potentially improving patient compliance. The positive results from similar combination approaches in other trials, such as the AFFINITY trial, further validate Spyre’s strategy and support the potential for their therapies to break the therapeutic ceiling seen with current treatments.
Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Celldex, and DBV Technologies SA – American. According to TipRanks, Slutsky has an average return of 10.9% and a 40.05% success rate on recommended stocks.
In another report released on August 6, Leerink Partners also reiterated a Buy rating on the stock with a $45.00 price target.